RCT | Assessing low-dose ketamine’s antidepressant & antisuicidal effects in patients with treatment-resistant depression
5 Apr, 2023 | 13:44h | UTC
Commentary on Twitter
RCT: ketamine infusion (0.5 mg/kg) is a safe and effective treatment for patients with TRD and prominent suicidal ideation vs. midazolam. Response was noted when the current depressive episode lasted for <24 months and the number of failed AD is ≤4 https://t.co/QKNy8bUKBK pic.twitter.com/GyfQp0pmpO
— PfOL (@psychopharmacol) April 4, 2023